First Quadrant L P CA increased its position in Quest Diagnostics Incorporated (NYSE:DGX) by 0.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 178,997 shares of the medical research company’s stock after buying an additional 1 shares during the period. First Quadrant L P CA owned about 0.13% of Quest Diagnostics worth $19,897,000 at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in DGX. YorkBridge Wealth Partners LLC increased its stake in Quest Diagnostics by 1.5% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,188 shares of the medical research company’s stock worth $127,000 after buying an additional 18 shares in the last quarter. Parallel Advisors LLC increased its stake in Quest Diagnostics by 16.1% in the first quarter. Parallel Advisors LLC now owns 1,279 shares of the medical research company’s stock worth $137,000 after buying an additional 177 shares in the last quarter. Advisors Capital Management LLC purchased a new stake in Quest Diagnostics during the first quarter worth $164,000. Trust Co. of Vermont increased its stake in Quest Diagnostics by 8.5% in the first quarter. Trust Co. of Vermont now owns 1,859 shares of the medical research company’s stock worth $182,000 after buying an additional 145 shares in the last quarter. Finally, Perkins Capital Management Inc. purchased a new stake in Quest Diagnostics during the first quarter worth $201,000. 90.65% of the stock is owned by hedge funds and other institutional investors.
Quest Diagnostics Incorporated (NYSE DGX) traded up 0.08% on Thursday, reaching $110.02. The company had a trading volume of 158,269 shares. Quest Diagnostics Incorporated has a 12-month low of $79.12 and a 12-month high of $112.97. The stock has a market capitalization of $15.05 billion, a P/E ratio of 22.15 and a beta of 0.70. The stock’s 50-day moving average price is $109.18 and its 200-day moving average price is $101.35.
Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings data on Thursday, April 20th. The medical research company reported $1.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.18 by $0.15. The business had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.87 billion. Quest Diagnostics had a return on equity of 15.22% and a net margin of 9.34%. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.12 EPS. On average, equities research analysts anticipate that Quest Diagnostics Incorporated will post $5.57 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 24th. Investors of record on Monday, July 10th will be issued a dividend of $0.45 per share. The ex-dividend date of this dividend is Thursday, July 6th. This represents a $1.80 dividend on an annualized basis and a yield of 1.64%. Quest Diagnostics’s dividend payout ratio (DPR) is 36.29%.
COPYRIGHT VIOLATION WARNING: “Quest Diagnostics Incorporated (NYSE:DGX) Shares Bought by First Quadrant L P CA” was reported by BNB Daily and is the property of of BNB Daily. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.baseball-news-blog.com/2017/07/20/quest-diagnostics-incorporated-nysedgx-shares-bought-by-first-quadrant-l-p-ca.html.
A number of research firms have recently weighed in on DGX. UBS AG raised Quest Diagnostics from a “market perform” rating to an “outperform” rating in a report on Friday, April 21st. Evercore ISI reissued an “in-line” rating and set a $104.50 target price on shares of Quest Diagnostics in a report on Wednesday, June 28th. Barclays PLC reissued a “hold” rating and set a $110.00 target price on shares of Quest Diagnostics in a report on Wednesday. Mizuho lifted their target price on Quest Diagnostics from $115.00 to $122.00 and gave the stock a “buy” rating in a report on Monday, June 5th. Finally, Canaccord Genuity reissued a “buy” rating and set a $118.00 target price on shares of Quest Diagnostics in a report on Tuesday, June 13th. Eight research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Quest Diagnostics has an average rating of “Buy” and an average price target of $110.50.
In other Quest Diagnostics news, Director Jenne K. Britell sold 6,111 shares of the firm’s stock in a transaction dated Monday, April 24th. The stock was sold at an average price of $104.03, for a total value of $635,727.33. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Catherine T. Doherty sold 59,762 shares of the firm’s stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $107.55, for a total value of $6,427,403.10. Following the completion of the sale, the senior vice president now directly owns 78,582 shares in the company, valued at approximately $8,451,494.10. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company’s stock.
About Quest Diagnostics
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).